Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
2.760
+0.440 (+18.97%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
↗
March 28, 2023
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...
Via
Benzinga
OKYO Pharma Announces PDMR Dealing
March 24, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov
↗
March 17, 2023
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public...
Via
Benzinga
Why Is Okyo Pharma (OKYO) Stock Up 13% Today?
↗
March 16, 2023
Okyo Pharma (OKYO) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of DED treatment OK-101.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 16, 2023
Via
Benzinga
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
March 16, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
March 14, 2023
Via
Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
March 14, 2023
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...
Via
Benzinga
UBER, LYFT Stocks Rise as California Court Rules Drivers Are Contractors
↗
March 14, 2023
Uber (UBER) and Lyft (LYFT) stock are on the rise Tuesday after a court ruled that the companies' drivers are contractors.
Via
InvestorPlace
Why Is OKYO Pharma (OKYO) Stock Down 10% Today?
↗
March 14, 2023
OKYO Pharma (OKYO) stock is heading lower on Tuesday after the company revealed details of a stock offering for its ADSs.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 14, 2023
Via
Benzinga
Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
↗
March 14, 2023
Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
March 14, 2023
We're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday!
Via
InvestorPlace
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
March 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
March 13, 2023
Via
Benzinga
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
March 13, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
March 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
↗
March 01, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
US Stocks Edge Lower; Dollar Tree Profit Beats Views
↗
March 01, 2023
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 30 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.09% to 32,626.82 while...
Via
Benzinga
Why Is Helbiz (HLBZ) Stock Up 37% Today?
↗
March 01, 2023
Helbiz (HLBZ) stock is on the move Wednesday despite a lack of hard news concerning the electric bike and scooter company.
Via
InvestorPlace
XPEV Stock Alert: What to Know as Xpeng Reports February Vehicle Deliveries
↗
March 01, 2023
Xpeng (XPEV) stock is worth checking on Wednesday after the electric vehicle (EV) company released delivery data for February.
Via
InvestorPlace
Why Is Novavax (NVAX) Stock Down 26% Today?
↗
March 01, 2023
Novavax (NVAX) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business.
Via
InvestorPlace
Why Is OKYO Pharma (OKYO) Stock Down 31% Today?
↗
March 01, 2023
OKYO Pharma (OKYO) stock is taking a beating on Wednesday despite recent progress toward a Phase 2 clinical trial for dry eye treatment.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
March 01, 2023
Via
Benzinga
OKYO Pharma's Drug OK-101 Clears Customs in the US; To Be Used In Phase 2, First-In-Human, Clinical Trial For Patients With Dry Eye Disease
↗
March 01, 2023
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) recently announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was...
Via
Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
↗
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
March 01, 2023
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
February 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today